Replies to post #25165 on NanoViricides Inc. (NNVC)

[BonelessCat]

Not only can they be duplicated, but improved upon. The initial proof of concept tests of 2005 and 2006 were based on targeted ligands specific to virus types. Around that same time, Diwan and staff began to look at sialic acid binding sites and clipped ligands that exploited those sites. The result became the base nanomicelle, and it would seem increased efficacy substantially.

So, not only are those results duplicable, but over time results have demonstrated increased efficacy, something that most often can't be achieved by other approaches, such as toxic compounds or inhibitors.